During the 2018 annual American Society of Hematology (ASH) meeting, I was hosted by CLL Society and Dr. Brian Kauffman to discuss recent research I had presented at that meeting on the economic impact of using venetoclax versus chemotherapy or chemoimmunotherapy for patients with CLL. This was a poster presentation that generated a lot of
As patents for biologics emerge on the marketplace, what will be their role within the cancer community? Will biosimilars provide alternatives for cancer treatment? In addition to alternatives, what information and education is needed for stakeholders to make informed choices about the cancer treatments? During the 2018 annual American Society of Clinical Oncology (ASCO) meeting,
I was honored to be invited to the 2018 Summit on National and Global Cancer Health Disparities which was held from April 28-29 in Seattle, WA. During the meeting, I participated in a panel debate discussion on “who is responsible for rising costs of cancer care”. I was joined by fellow panelists included Don Harison,
How do clinical pathways help in reducing the rising cost of healthcare? how do healthcare executives proceed in implementing clinical pathways in their respective systems in a way that assures buy-in from their stakeholders, maintaining patients’ access to life saving therapies, and contenting to bend the cost curve? I provide some suggestions to healthcare executives
During the 2016 American Society of Hematology (ASH) meeting, I was interviewed by OBR to offer an opinion on how payers are implementing clinical pathways in how they provide coverage to patients with hematologic malignancies. Pathways are not always welcome by physicians and healthcare providers and there is always a debate about their value. In
I was interviewed by OBR during the 2016 annual American Society of Hematology (ASH) meeting, and was asked about important CLL presentations that took place during that meeting. At the time, I was a VP and CMO at Cardinal Health Specialty Solutions.
During the 2016 American Society of Hematology (ASH) meeting, I was interviewed about how clinical pathways could be integrated as part of managing patients with chronic lymphocytic leukemia (CLL). Pathways are suggested to reduce variability in care but some oppose pathways as infringing on clinical decision-making. At the time of this OBR interview, I was
Dr. Nabhan has been podcasting for years. His first podcast “Outspoken Oncology” started in February 2019 and won him two communication awards especially with dedicated coverage to COVID-19 when the pandemic started. That podcast retired in the summer of 2020 and Dr. Nabhan currently hosts two podcasts:
Healthcare Unfiltered: unedited and daring podcast tackling all aspects of healthcare hosting thought leaders from all over the world addressing timely and relevant debates that are important to everyone in the healthcare industry
HemOnc Pulse: Started in December 2022 and is dedicated to hematology and only hematology. Dr. Nabhan hosts thought leaders in the field of hematology discussing recent updates, new published research, debates, and asks questions that are essential to clinical care. This podcast is sponsored by Blood Cancers Today and SOHO.
